Krka DDLTS:0HLK 78 EBITDA Margin % is 30.49% as of Mar. 2026, which is 14% above its 10-year median of 26.67. GuruFocus rates LTS:0HLK with a GF Score™ of 78/100 and a GF Value™ of €38.09 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Krka DD ranks better than 81.83% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Krka DD's EBITDA for the
three
months ended in Mar. 2026 was €173 Mil. Krka DD's Revenue for the
three
months ended in Mar. 2026 was €566 Mil. Therefore, Krka DD's EBITDA margin for the quarter that ended in Mar. 2026 was 30.49%.
Krka DD (LTS:0HLK) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Krka DD EBITDA Margin % Related Terms
Krka DD EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Krka DD's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HLK vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Krka DD's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (LTS:0HLK) has a EBITDA Margin % of 30.49% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Krka DD and its competitors. This is 14% above median its historical median of 26.67. Over the past decade, Krka DD's EBITDA Margin % has ranged from 18.97 to 31.56. According to the industry distribution chart, Krka DD ranks #173 out of 952 companies in the Drug Manufacturers industry, placing it in the top 18.2%.
Is Krka DD's EBITDA Margin % too high?
Krka DD's current EBITDA Margin % of 30.49% is 14% above median its 10-year median of 26.67. Over the past 10 years, this metric has ranged from a low of 18.97 to a high of 31.56. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Krka DD's value of 30.49% is 144.5% above this industry median. Based on the distribution chart, Krka DD ranks #173 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Krka DD has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #173 out of 952 companies for EBITDA Margin %. This places Krka DD in the top 18% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Krka DD's value of 30.49% is 144.5% above this benchmark. Historically, Krka DD's own EBITDA Margin % has ranged from 18.97 to 31.56 over the past decade. While the company's 10-year median is 26.67 vs. the industry median of 12.47, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current EBITDA Margin % of 30.49% is 144.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current EBITDA Margin % is 30.49%, which is 14% above median its own 10-year median of 26.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (LTS:0HLK) is currently considered Significantly Overvalued. The stock's GF Value™ is €38.09, compared to a current price of €64.80 — trading 70.1% above its estimated fair value. The current EBITDA Margin % is 30.49%, which is 14% above median its 10-year median of 26.67 and 144.5% above the Drug Manufacturers industry median of 12.47. Krka DD's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Krka DD (LTS:0HLK), the current EBITDA Margin % is 30.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (LTS:0HLK) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €64.80 is trading 70.1% above its estimated GF Value™ of €38.09.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for LTS:0HLK:
EBITDA Margin %: 30.49% (14% above median its 10-year median of 26.67)
GF Value™: €38.09 vs. price of €64.80 (70.1% above fair value)
Industry Position: 144.5% above the Drug Manufacturers median (#173 of 952)
No single metric tells the full story. See the LTS:0HLK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
78GF Score
Get the complete analysis for LTS:0HLK
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HLK has been successfully added to your 
